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Abstract 
Aims 
Anaemia is increasingly recognised as having an independent impact upon 
patient outcomes in cardiac disease. The role of novel iron therapies to treat 
anaemia is increasing. This systematic review and meta-analysis assesses the 
efficacy and safety of iron therapies for the treatment of adults with anaemia.  
Methods and Results 
Electronic databases and search engines were searched as per Cochrane 
methodology. Randomised controlled trials (RCTs) of iron versus inactive 
control or placebo, as well as alternative formulations, doses and routes in 
anaemic adults without chronic kidney disease or in the peri-partum period 
were eligible. The primary outcome of interest was mortality at one year. 
Secondary outcomes were blood transfusion, haemoglobin levels, quality of life, 
serious adverse events and length of hospital stay.  
64 RCTs (including five studies of heart failure patients) including 9004 
participants were included. None of the studies were at a low risk of bias. There 
were no statistically significant differences in mortality between iron and 
inactive control. Both oral and parenteral iron significantly reduced the 
proportion of patients requiring blood transfusion compared to inactive control 
(risk ratio (RR) 0.66 (95% confidence interval (CI) 0.48 to 0.90) and RR 0.84 
(95% CI 0.73 – 0.97) respectively. Haemoglobin was increased more by both oral 
and parenteral iron compared to inactive control (mean difference (MD) 0.91 
g/dL (95% CI 0.48 to 1.35) and MD 1.04 (95% CI 0.52 to 1.57) respectively), and 
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parenteral iron demonstrated a greater increase when compared to oral iron 
(MD 0.53 g/dL (95% CI 0.31 to 0.75)). In all comparisons there were no 
differences in the results comparing patients with and without heart failure. 
Conclusion 
Both oral and parenteral iron are shown to decrease the proportion of people 
who require blood transfusion and increase haemoglobin levels, without any 
benefit in mortality. Further trials at a low risk of bias, powered to measure 
clinically significant endpoints are still required.  
* This paper updates the findings of a Cochrane review first published December 
2014 in The Cochrane Database of Systematic Reviews (CDSR) Issue 12 
(http://www.thecochranelibrary.com).  
Cochrane Database of Systematic Reviews 2014, Issue 12. Art. No.: CD010640. DOI: 
10.1002/14651858.CD010640.pub2.  
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Introduction  
Anaemia has a high worldwide prevalence, and is estimated to affect 1.6 billion 
people worldwide.(1) The World Health Organisation (WHO) defines anaemia as 
a circulating haemoglobin concentration of <120 g/L in non-pregnant women 
and <130 g/L in men.(1)  
Anaemia can cause fatigue and decreased work activity.(2) It has been shown to 
worsen heart failure (3) and is associated in increased mortality in people with 
chronic heart failure.(4) Anaemia is also associated with worse outcomes after 
cardiac and non-cardiac surgery, including increased mortality and hospital 
length of stay.(5, 6) 
Approximately 50% of anaemia is due to iron deficiency.(1, 7, 8) Absolute iron 
deficiency can be caused by nutritional deficiency of iron, loss due to bleeding or 
decreased absorption of dietary iron, causing a lack of stored iron. Alternatively, 
a state of functional iron deficiency can occur, leading to iron restricted 
erythropoiesis despite normal iron stores.  Functional iron deficiency can be 
caused by: defective incorporation of iron into developing red cells, decreased 
availability of iron stores as the result of increased uptake and retention of iron 
within the reticuloendothelial system or failure of absorption of intestinal iron 
due to inflammation, mediated by hepcidin. Chronic inflammation and disease 
may lead to increased hepcidin levels and thus anaemia of chronic disease.(9) 
European Society of Cardiology guidelines recommend the diagnosis and 
treatment of correctable causes of anaemia in heart failure.(10) There has been 
considerable attention in cardiac disease on the role of iron therapy for iron 
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deficiency but the efficacy and effect of iron therapy to treat anaemia remains 
uncertain. 
This review updates findings published in the Cochrane Database of Systematic 
Reviews in 2014,(11) to assess the safety and efficacy of iron therapies for the 
treatment of adults with anaemia who are not pregnant or lactating and do not 
have CKD. No previous systematic review had been performed to assess the 
clinical benefits of iron therapies excluding these groups. It is important that the 
effectiveness of iron can be explored in a wide range of clinical conditions and 
this review can influence the care of many patient groups. This is particularly 
important with the burgeoning interest in patient blood management. The 
increased awareness of the importance of detecting and treating anaemia and 
reducing unnecessary or inappropriate blood transfusions includes forthcoming 
National Institute of Health and Care Excellent (NICE) guidelines for 
transfusion.(12) 
 
Methods 
The Cochrane methodology was applied to this review.(11) Table 1 presents the 
inclusion and exclusion criteria of studies.  
As per the Cochrane Handbook for Systematic Reviews of Interventions (13) all 
known relevant electronic databases and search engines were accessed.  
Searches were not restricted by language, date or publication status. The 
following databases were searched until November 2014: Cochrane Central 
Register of Controlled Trials (The Cochrane Library) (Issue 7, 2013), MEDLINE 
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(Ovid) (1950-), EMBASE (Ovid) (1980-), CINAHL (Cumulative Index to Nursing 
and Allied Health Literature) Plus (1957-), ISI Web of Science: Science Citation 
Index Expanded (SCI-EXPANDED) (1970-) and ISI web of Science: Conference 
Proceedings Citation Index-Science (CPCI-S) (1990-). The reference lists of all 
included studies and previously published reviews were searched for additional 
studies. Search terms included: iron, ferrous, ferric, an(a)emia/c. Full details of 
the search strategy are available.(11) 
 Study selection 
Iron therapy can be administered by a variety of routes and in different 
formulations.(20) Randomised controlled trials (RCTs) of iron (oral and 
parenteral) versus control or placebo, as well as alternative formulations, doses 
and routes, were eligible to be included in the meta-analysis. RCTs irrespective of 
blinding, language, publication status and date of publication, study setting and 
sample size were included. Any non-peripartum anaemic adults without chronic 
kidney disease were included in this review, irrespective of the setting and the 
degree of anaemia. The primary outcome of interest was mortality at one year. 
Risk of bias was assessed as per the instructions of the Cochrane Handbook(13) 
according to the following domains: sequence generation, allocation 
concealment, blinding of participants and personnel, blinding of outcome 
assessors, incomplete outcome data, selective outcome reporting and source of 
funding bias.  
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Two review authors (KSG and TR or BC) identified trials for inclusion 
independently of each other, listing excluded studies and the reason for 
exclusion. Differences were resolved by discussion.  
 Statistical Analysis 
Meta-analyses were performed using the software package Review Manager 
version 5.3(18) and in accordance with the recommendations of the Cochrane 
Handbook.(13) The results of the random effects model were reported. The risk 
ratio (RR) with 95% confidence interval (CI) was calculated for dichotomous 
variables, and the mean difference (MD) with 95% CI or standardised mean 
difference (SMD) with 95% CI as appropriate for continuous variables. For time-
to-event outcomes such as mortality at maximal follow-up, hazard ratio (HR) 
with 95% CI was calculated.  
Subgroup analyses were performed for trials studying participants chronic heart 
failure compared to those without. Subgroup analyses were also performed in 
trials in which erythropoietin was used as a co-intervention versus those that did 
not, and by participant group: blood loss conditions, cancer, pre-operative, 
autoimmune and miscellaneous (See supplementary online appendix for these 
results). Test for subgroup differences within Review Manager was used, with a 
P value of <0.05 considered statistically significant.  
Sensitivity analysis was planned to exclude trials with unclear or high risk of bias 
for random sequence generation; unclear or high risk of bias due to lack of 
blinding of participants, healthcare providers or outcome assessors; and unclear 
or high risk of bias due to incomplete outcome data. However, all trials had at 
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least one domain with unclear or high risk of bias. Sensitivity analysis was 
performed by excluding trials in which we imputed the mean and the standard 
deviation, when there were at least two trials for the outcome. (See 
supplementary online appendix for sensitivity analysis results). 
 
Results 
Study selection 
Overall, 225 full text publications from 17693 citations were identified as 
potentially relevant studies and full text copies were retrieved and assessed. 
Exclusions are detailed in Figure 1: Study selection flow diagram.  In total 128 
publications describing 65 RCTs fulfilled the inclusion criteria. Duplicate 
reporting included the publication of conference abstracts prior to publication 
and publication of subset analysis, cost analysis and combined reporting.  
Study characteristics 
Overall, 9004 participants were included in the 65 RCT’s that provided the 
quantitative data for this review. (See Tables 2 and 3 and Supplementary 
Appendix Table 1 for individual study details) None of the studies included were 
of a low risk of bias in every domain. A summary of the risk of bias analysis is 
presented in the Supplementary Appendix. 
 
Results 
Mortality 
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The primary outcome of interest was mortality at one year. However, only one 
trial reported mortality at one year,(20) (in which the mortality in both oral iron 
and no iron group was 29% (p=1)) therefore hazard ratio was not calculated for 
any of the comparisons.  
Eight studies investigated oral iron vs. inactive control and reported mortality, 
(20, 23, 60-64, 66) 19 studies compared parenteral iron vs. inactive control (27, 
29, 31-33, 35-40, 45, 46, 60-64, 66) and 13 trials reported mortality comparing 
parenteral iron vs. oral iron.(47, 48, 51, 53-55, 57, 60-64, 66) (Figures 2-4) In all 
comparisons there was no statistically significant difference in mortality. (Table 
4) 
Proportion requiring blood transfusion 
Comparing oral iron vs. inactive control,(19, 21, 62, 64, 66) there was a lower 
transfusion rate in the oral iron group (RR 0.66 (95% CI 0.48 to 0.90)). 
(Supplementary Appendix Figure 1) When comparing parenteral iron vs. inactive 
control statistically significant differences in participants who received blood 
transfusion were shown (RR 0.84, 95% CI 0.73 to 0.97). (27, 29-35, 38, 43, 45, 46, 
62, 64, 66) (Supplementary Appendix Figure 2) In those studies that reported 
mean blood transfused, this was significantly lower in the parenteral iron group 
than the inactive control group (MD -1.71 units; 95% CI -3.20 to -0.22). (29, 32, 
34, 48) No statistically significant difference between the two groups was found 
comparing parenteral to oral iron. (47, 48, 62, 64, 66)(Figure 5) (Table 4)  
Haemoglobin 
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Oral iron resulted in higher haemoglobin levels compared to inactive controls 
(MD 0.91 g/dL (95% CI 0.48 to 1.35); I2=67%; chi2 test for heterogeneity 
P=0.0004). (20, 22-26, 60-65) There was significant heterogeneity (I2=67%), 
with a point estimate of the mean difference in haemoglobin levels ranging from 
0.2 g/dL to 2.2 g/dL higher in the oral iron group than in the inactive control 
group. (Supplementary Appendix figure 3) Parenteral iron resulted in higher 
haemoglobin levels than inactive controls (MD 1.04 (95% CI 0.52to1.57); 
I2=93%; Chi2 test for heterogeneity P<0.00001)). (27, 30- 33, 35, 36, 38-48, 50, 
60, 61, 63-66, 68-70) (Supplementary Appendix figure 4) Again there was 
considerable heterogeneity (I2=93%), with a point estimate of the mean 
difference in haemoglobin levels ranging from -0.7 g/dL to 3 g/dL higher in the 
parenteral iron group than in the inactive control group. Comparing parenteral 
vs. oral iron, haemoglobin concentration was higher in the parenteral iron group 
(MD 0.53 (95% CI 0.31 to 0.75). (47, 48, 50-58, 60-65)(Figure 6) 
Quality of life 
Six trials reported quality of life when comparing parenteral iron to inactive 
control (27, 29, 39, 40, 46, 66) using a variety of scales. Quality of life was higher 
in the parenteral iron group than the control group SMD 0.22 ((95% CI -0.00 to 
0.45); I2= 74%; chi2 test for heterogeneity P=0.002). (Figure 7) When comparing 
parenteral and oral iron, there was no significant difference in quality of life 
(SMD 0.01 (95% CI -0.09 to 0.12)). (47, 48, 51, 55-57, 66)(Figure 8) 
Serious adverse events 
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In comparisons of oral iron vs. inactive control, (20, 23-25, 60, 62, 64, 66) and 
parenteral iron vs. inactive control, (27, 31, 32, 34, 37, 40, 46, 60, 62, 64, 66) 
there were no statistically significant differences found. (Supplementary 
Appendix figure 5 and 6) Importantly, no trials reported severe allergic reactions 
from parenteral iron.  There was no statistically significant difference in serious 
adverse events when comparing parenteral to oral iron. (47, 48, 50-55, 57, 58, 60, 
62, 64, 66) (Figure 9) (Table 4) 
Length of hospital stay 
One study compared length of hospital stay for oral iron vs. inactive control,(20) 
whilst one trial compared length of hospital stay for parenteral versus oral 
iron;(47) neither showed any significant difference.  
Subgroup Analysis – Chronic Heart Failure 
Only one study included comparison of oral to parenteral iron, and oral iron to 
inactive control in heart failure, reporting mortality and haemoglobin 
concentration.(63) Subgroup analysis of oral to parenteral iron in patients with 
heart failure versus those without revealed no significant subgroup differences 
in mortality (p=0.44) or haemoglobin (p=0.59). When comparing oral iron to 
inactive control in patients with and without heart failure there was no 
significant difference in mortality (p=0.39) and haemoglobin concentration 
(p=0.93) between the groups.  
Comparing parenteral iron to inactive control in patients with and without heart 
failure showed no significant difference in mortality (p=0.79), haemoglobin 
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(p=0.99), quality of life (p=0.95) or serious adverse events (p=0.14) between 
these groups.  
In patients with heart failure the point estimate haemoglobin concentration was 
significantly higher in patients given intravenous iron compared to placebo (MD 
1.12 (95%CI 0.11 to 2.14), yet without any significant difference in mortality, 
quality of life or serious adverse events.  
Heterogeneity 
The heterogeneity within the studies ranged from low (for mortality, I2=0, and 
serious adverse events, to considerable for haemoglobin (I2=67% for oral iron vs. 
inactive control, I2=93% for parenteral iron vs. inactive control and I2=41% for 
parenteral vs. oral iron. 
 
Discussion 
This systematic review reviewed the utility of iron therapy for the treatment of 
anaemia in non-peripartum anaemic adults without chronic kidney disease. Most 
of the trials included patients with mild to moderate anaemia. The trials did not 
demonstrate clinical benefit in terms of mortality. In all comparisons there were 
no significant subgroup differences in the results comparing patients with and 
without heart failure.  
Both oral and parenteral iron led to higher level of haemoglobin compared to 
inactive controls, and parenteral iron demonstrated a statistically significant rise 
in comparison to oral iron.  
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Parenteral iron demonstrated a statistically significant benefit in quality of life 
when compared to inactive control but no significant difference when compared 
to oral iron. It was not possible to estimate the clinical importance of this 
difference. The only trial comparing oral iron to inactive control showed no 
statistically significant difference.(66)  
Both oral iron and parenteral iron demonstrated a significant reduction in the 
risk of blood transfusion when compared to inactive control, with no significant 
difference between the two modes of administration when compared to one 
another.   
There was no significant difference in the proportion of patients who developed 
serious adverse events as a result of parenteral or oral iron therapy. Most trials 
reporting serious adverse events reported that there were no allergic or 
anaphylactic reactions or serious reactions, suggesting that these are rare.  
Parenteral iron was demonstrated to result in increased haemoglobin levels and 
a reduction in blood transfusion when compared to inactive controls, without 
any statistically significant increase in adverse events. However, no 
improvement in quality of life or mortality was demonstrated in these studies.   
Most of the adverse events related to oral iron therapy were gastrointestinal side 
effects such as nausea, diarrhoea or constipation. While the balance of the 
benefits and harms of oral iron therapy appear to favour routine oral iron 
therapy in anaemic patients, the quality of evidence is very low. There were no 
significant clinical benefits of one iron preparation or regimen over another. 
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Thus, there is little evidence on to recommend one preparation or regimen over 
another. 
Subgroup analyses were performed to determine whether iron would be useful 
in specific clinical situations or whether iron therapy might be useful in patients 
who are receiving erythropoietin. The results were not consistent enough to 
enable us determine this. In anaemic patients with heart failure, iron improved 
the haemoglobin concentration without any improvement in other clinically 
relevant endpoints.   
This analysis is applicable only in non-peripartum anaemic adults without 
chronic kidney disease with mild to moderate anaemia. It should also be noted 
that most trials excluded patients who were allergic to iron therapy and 
measured the ferritin and transferrin levels to ensure that the patients had iron 
deficiency anaemia.  
None of the trials were of a low risk of bias in every domain assessed. Many trials 
did not report important clinical outcomes, although it is likely that such clinical 
outcomes were measured. This has resulted in significant selective outcome 
reporting bias. We did found evidence of publication bias in haemoglobin levels 
and we found evidence of selective reporting, i.e. many clinical trials reported 
haemoglobin levels but not clinical outcomes. We imputed the mean and 
standard deviation when these were not available. This could have introduced 
bias. However, there was no evidence of such a bias when exclusion of trials with 
imputed data did not alter the results significantly.  
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The previous systematic review of iron in non-pregnant and non-lactating 
anaemic adults without chronic kidney disease failed to show any clinical benefit 
of intravenous iron compared to oral iron or inactive controls beyond improving 
haemoglobin levels.(11) This expanded meta-analysis showed a statistical 
difference in blood transfusion rates and quality of life for parenteral iron when 
compared to inactive control. However, the clinical significance of this is not 
known, particularly since there was no difference in mortality rates. There is a 
growing recognition that anaemia is a significant comorbidity in patients that 
may not be modifiable, whether by iron replacement, or blood transfusion. In 
heart failure, treatment of iron deficiency itself may be more important than 
anaemia per se.  
The recognition of functional iron deficiency modulated by hepcidin, and its 
associate with inflammation provides an explanation for the efficacy of 
parenteral iron when compared to oral iron in producing a rise in haemoglobin 
in anaemic patients.  In spite of demonstrating a greater haemoglobin response 
than oral iron, parenteral iron failed to show any other benefits over oral 
preparations.  
In the context of heart failure with or without anaemia, intravenous iron has 
been shown to reduce readmission to hospital,(84) and to improve renal 
function.(85) Iron replacement is recommended for all iron deficient patients 
with heart failure, regardless of whether they are anaemic. The majority of 
patients with heart failure receive oral iron, despite evidence lacking for its 
benefit in these patients.(86) Only one trial comparing oral versus intravenous 
iron in anaemic patient with heart failure was included in this systematic 
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review,(63) and further trials are required comparing oral to intravenous iron in 
anaemic patients with heart failure.   
Recently, a systematic review was published which included all trials in which 
intravenous iron was compared with either oral iron or no iron therapy 
irrespective of the clinical setting.(87) Our findings are broadly similar to that 
review which found that intravenous iron increased haemoglobin levels and 
decreased transfusion requirements. However, that systematic review found 
infective complications higher with intravenous iron. In this review, there were 
no significant differences in the serious adverse events. However, the confidence 
intervals were wide and so the observation is our systematic review might have 
been due to lack of evidence of effect rather than lack of effect. 
In conclusion, intravenous iron is effective in improving haemoglobin levels 
compared to oral iron or inactive controls. Oral iron improves haemoglobin 
levels in comparison to inactive control. Neither reduced mortality, however 
both reduced blood transfusion rates, and parenteral iron demonstrated 
statistically significant improvement in quality of life, although the clinical 
significance of this increase is not known. The analysis of trials of heart failure 
patients within this study showed the same outcomes. From these findings, more 
randomised controlled trials at a low risk of bias, powered to measure clinically 
useful endpoints including mortality, blood transfusion and quality of life are still 
required in all patient populations, including those with heart failure.  
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Figure Legends 
Table 1: Inclusion and exclusion criteria 
WHO – World Health Organisation; Hb – haemoglobin 
Table 2: Characteristics of included studies 
Table 3: Clinical setting of included studies 
Table 4: Summary of results 
RR – Risk Ratio; CI – Confidence Interval; MD – Mean Difference; SMD – 
Standardised Mean Difference; SE – Standard Error  
* Denotes statistical significance 
Figure 1: Study selection flow diagram 
Figure 2: Oral iron vs inactive control - Mortality 
Forest plot of risk ratios (RRs) with 95% confidence intervals (CIs) comparing 
oral iron with inactive control for mortality. 
Squares indicate study-specific RR estimates; horizontal lines indicate the 95% 
CI; diamonds indicate the pooled RRs with their 95% CI. 
Figure 3: Parenteral Iron vs Inactive Control: Mortality 
Forest plot of risk ratios (RRs) with 95% confidence intervals (CIs) comparing 
parenteral iron with inactive control for mortality.  
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Squares indicate study-specific RR estimates; horizontal lines indicate the 95% 
CI; diamonds indicate the pooled RRs with their 95% CI.  
Figure 4: Parenteral vs Oral Iron: Mortality 
Forest plot of risk ratios (RRs) with 95% confidence intervals (CIs) comparing 
parenteral with oral iron for mortality.  
Squares indicate study-specific RR estimates; horizontal lines indicate the 95% 
CI; diamonds indicate the pooled RRs with their 95% CI.  
Figure 5: Parenteral vs Oral Iron: Proportion requiring blood transfusion 
Forest plot of risk ratios (RRs) with 95% confidence intervals (CIs) comparing 
parenteral with oral iron for blood transfusion.  
Squares indicate study-specific RR estimates; horizontal lines indicate the 95% 
CI; diamonds indicate the pooled RRs with their 95% CI.  
Figure 6: Parenteral vs Oral Iron: Haemoglobin 
Forest plot of mean differences (MDs) with 95% confidence intervals (CIs) 
comparing parenteral with oral iron for haemoglobin concentration.  
Squares indicate study-specific MD estimates; horizontal lines indicate the 95% 
CI; diamonds indicate the pooled RRs with their 95% CI.  
Figure 7: Parenteral Iron vs Inactive Control: Quality of Life 
Forest plot of standardised mean differences (SMDs) with 95% confidence 
intervals (CIs) comparing parenteral iron with inactive control for effect upon 
quality of life.  
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Squares indicate study-specific SMD estimates; horizontal lines indicate the 95% 
CI; diamonds indicate the pooled RRs with their 95% CI.  
Figure 8: Parenteral vs Oral Iron: Quality of Life 
Forest plot of standardised mean differences (SMDs) with 95% confidence 
intervals (CIs) comparing parenteral with oral iron for effect upon quality of life.  
Squares indicate study-specific SMD estimates; horizontal lines indicate the 95% 
CI; diamonds indicate the pooled RRs with their 95% CI.  
Figure 9: Parenteral vs Oral Iron: Serious adverse events 
Forest plot of risk ratios (RRs) with 95% confidence intervals (CIs) of serious 
adverse events comparing parenteral iron with inactive control.  
Squares indicate study-specific RR estimates; horizontal lines indicate the 95% 
CI; diamonds indicate the pooled RRs with their 95% CI. 
 
 
 
 
 
 
 
 
